KD Logo

Bernstein’s latest rating for IONS stock

Ionis Pharmaceuticals Inc’s filing revealed that its Director BERTHELSEN SPENCER R unloaded Company’s shares for reported $0.64 million on Jun 17 ’24. In the deal valued at $40.29 per share,16,000 shares were sold. As a result of this transaction, BERTHELSEN SPENCER R now holds 147,257 shares worth roughly $6.79 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, KLEIN JOSEPH III sold 6,000 shares, generating $256,277 in total proceeds. Upon selling the shares at $42.71, the Director now owns 0 shares.

Before that, Baroldi Joseph sold 4,006 shares. Ionis Pharmaceuticals Inc shares valued at $166,641 were divested by the EVP, Chief Business Officer at a price of $41.60 per share. As a result of the transaction, Baroldi Joseph now holds 19,631 shares, worth roughly $0.9 million.

Bernstein upgraded its Ionis Pharmaceuticals Inc [IONS] rating to a Mkt perform from a an Underperform in a research note published recently. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who increased its forecast for the stock in early April from “a Peer perform” to “an Outperform”. BofA Securities also remained covering IONS and has increased its forecast on January 02, 2024 with a “Buy” recommendation from previously “Neutral” rating. BofA Securities revised its rating on October 23, 2023. It rated IONS as “a Neutral” which previously was an “an Underperform”.

Price Performance Review of IONS

On Friday, Ionis Pharmaceuticals Inc [NASDAQ:IONS] saw its stock jump 1.07% to $46.09. Over the last five days, the stock has lost -2.41%. Ionis Pharmaceuticals Inc shares have fallen nearly -8.90% since the year began. Nevertheless, the stocks have risen 9.24% over the past one year. While a 52-week high of $54.44 was reached on 01/12/24, a 52-week low of $35.95 was recorded on 05/31/24. SMA at 50 days reached $41.01, while 200 days put it at $45.46. A total of 0.62 million shares were traded, compared to the trading of 1.07 million shares in the previous session.

Levels Of Support And Resistance For IONS Stock

The 24-hour chart illustrates a support level at 45.51, which if violated will result in even more drops to 44.94. On the upside, there is a resistance level at 46.50. A further resistance level may holdings at 46.92. The Relative Strength Index (RSI) on the 14-day chart is 63.82, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.12, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 29.72%. Stochastics%K at 66.43% indicates the stock is a holding.

The most recent change occurred on September 29, 2023 when Raymond James began covering the stock and recommended ‘”a Strong buy”‘ rating along with a $63 price target.

Most Popular